ACC/AHA Representative.
ACC/AHA Joint Committee on Clinical Practice Guidelines Liaison.
Circulation. 2020 Dec 22;142(25):e533-e557. doi: 10.1161/CIR.0000000000000938. Epub 2020 Nov 20.
Aim This executive summary of the hypertrophic cardiomyopathy clinical practice guideline provides recommendations and algorithms for clinicians to diagnose and manage hypertrophic cardiomyopathy in adult and pediatric patients as well as supporting documentation to encourage their use. Methods A comprehensive literature search was conducted from January 1, 2010, to April 30, 2020, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Collaboration, Agency for Healthcare Research and Quality reports, and other relevant databases. Structure Many recommendations from the earlier hypertrophic cardiomyopathy guidelines have been updated with new evidence or a better understanding of earlier evidence. This summary operationalizes the recommendations from the full guideline and presents a combination of diagnostic work-up, genetic and family screening, risk stratification approaches, lifestyle modifications, surgical and catheter interventions, and medications that constitute components of guideline directed medical therapy. For both guideline-directed medical therapy and other recommended drug treatment regimens, the reader is advised to follow dosing, contraindications and drug-drug interactions based on product insert materials.
目的 本肥厚型心肌病临床实践指南执行摘要为临床医生提供了诊断和管理成人及儿科肥厚型心肌病的建议和算法，以及支持性文件，以鼓励他们使用这些建议和算法。
方法 从 2010 年 1 月 1 日至 2020 年 4 月 30 日，对PubMed、EMBASE、Cochrane 协作组织、美国医疗保健研究与质量局报告以及其他相关数据库中的英文文献进行了全面的文献检索，涵盖了针对人类受试者进行的研究、综述和其他证据。
结构 许多早期肥厚型心肌病指南中的建议都根据新证据或对早期证据的更好理解进行了更新。本摘要将完整指南中的建议付诸实施，并提出了诊断性检查、遗传和家族筛查、风险分层方法、生活方式改变、手术和导管介入以及构成指南指导下药物治疗的药物治疗等方面的综合建议。对于指南指导下的药物治疗和其他推荐的药物治疗方案，建议读者根据产品说明书中的剂量、禁忌和药物相互作用进行用药。
